Pfizer loses UK appeal over Moderna Covid-19 vaccine patent

UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Pfizer, Moderna vow appeals after split vaccine ruling

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.

Biotechnology

Moderna prevails in COVID-19 vaccine row at EPO

21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.

Europe

Moderna’s COVID-19 pledge dilemma

16 May 2024 As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.